Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CELU Celularity	$3.79 +5.0%	$2.66	$1.00 ▼ $5.22	$90.77M	0.79	169,381 shs	48,756 shs
ENTX Entera Bio	$1.94 -0.5%	$1.94	$1.50 ▼ $2.79	$88.59M	1.52	101,384 shs	35,204 shs
LSTA Lisata Therapeutics	$2.59 +4.9%	$2.62	$1.87 ▼ $4.20	$22.69M	0.93	31,735 shs	19,732 shs
OKYO OKYO Pharma	$2.37 +1.7%	$2.71	$0.85 ▼ $3.35	$89.14M	-0.09	173,076 shs	59,903 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for September 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CELU Celularity	-1.10%	+4.34%	-3.48%	+57.64%	+13.70%
ENTX Entera Bio	+2.63%	-1.02%	0.00%	0.00%	+18.18%
LSTA Lisata Therapeutics	+2.92%	-3.52%	-6.44%	-6.44%	-16.27%
OKYO OKYO Pharma	-5.28%	-11.74%	-15.27%	+25.95%	+126.21%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CELU Celularity	0.7365 of 5 stars	2.0	1.0	1.9	1.7	0.0
ENTX Entera Bio	1.1524 of 5 stars	2.0	3.0	2.8	0.8	0.0
LSTA Lisata Therapeutics	2.1678 of 5 stars	3.5	3.0	1.9	0.0	0.6
OKYO OKYO Pharma	2.4882 of 5 stars	3.5	5.0	0.6	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CELU Celularity	0.00	N/A	$6.00	59.36% Upside
ENTX Entera Bio	4.00	Strong Buy	$10.00	411.51% Upside
LSTA Lisata Therapeutics	3.00	Buy	$23.50	800.38% Upside
OKYO OKYO Pharma	3.00	Buy	$7.00	197.24% Upside

Current Analyst Ratings Breakdown

Latest LSTA, CELU, ENTX, and OKYO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2025	LSTA Lisata Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00
8/18/2025	CELU Celularity	WBB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Moderate Buy	$6.00
8/11/2025	ENTX Entera Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
7/15/2025	LSTA Lisata Therapeutics	Brookline Capital Management Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$20.00 ➝ $32.00

(Data available from 8/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CELU Celularity	$54.22M	1.66	N/A	N/A	$0.37 per share	10.18
ENTX Entera Bio	$166K	537.78	N/A	N/A	$0.38 per share	5.14
LSTA Lisata Therapeutics	$1M	22.86	N/A	N/A	$2.37 per share	1.10
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	($0.16) per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CELU Celularity	-$57.89M	-$2.65	N/A	∞	N/A	-106.77%	-271.88%	-42.82%	N/A
ENTX Entera Bio	-$9.54M	-$0.26	N/A	N/A	N/A	-4,525.11%	-77.75%	-68.13%	N/A
LSTA Lisata Therapeutics	-$19.99M	-$2.23	N/A	N/A	N/A	N/A	-69.68%	-59.44%	N/A
OKYO OKYO Pharma	-$4.71M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest LSTA, CELU, ENTX, and OKYO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/8/2025	Q2 2025	ENTX Entera Bio	-$0.11	-$0.06	+$0.05	-$0.06	N/A	N/A
8/7/2025	Q2 2025	LSTA Lisata Therapeutics	-$0.65	-$0.54	+$0.11	-$0.54	N/A	$0.07 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CELU Celularity	N/A	N/A	N/A	N/A	N/A
ENTX Entera Bio	N/A	N/A	N/A	N/A	N/A
LSTA Lisata Therapeutics	N/A	N/A	N/A	N/A	N/A
OKYO OKYO Pharma	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CELU Celularity	4.07	0.38	0.28
ENTX Entera Bio	N/A	10.47	10.47
LSTA Lisata Therapeutics	N/A	5.77	5.77
OKYO OKYO Pharma	N/A	0.40	0.40

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CELU Celularity	19.02%
ENTX Entera Bio	14.11%
LSTA Lisata Therapeutics	8.94%
OKYO OKYO Pharma	2.97%

Insider Ownership

Company	Insider Ownership
CELU Celularity	22.10%
ENTX Entera Bio	10.38%
LSTA Lisata Therapeutics	9.60%
OKYO OKYO Pharma	40.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CELU Celularity	220	23.95 million	18.66 million	Optionable
ENTX Entera Bio	20	45.66 million	40.92 million	Optionable
LSTA Lisata Therapeutics	30	8.76 million	7.92 million	Not Optionable
OKYO OKYO Pharma	7	37.61 million	22.39 million	Not Optionable

LSTA, CELU, ENTX, and OKYO Headlines

Recent News About These Companies

Wall Street Zen Upgrades OKYO Pharma (NASDAQ:OKYO) to Hold

August 11, 2025 | americanbankingnews.com

OKYO Pharma (NASDAQ:OKYO) Raised to "Hold" at Wall Street Zen

August 10, 2025 | marketbeat.com

Neuropathic corneal pain reduced in phase 2 trial of urcosimod

August 7, 2025 | healio.comH

Dauntless Investment Group LLC Invests $2.53 Million in OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO)

July 29, 2025 | marketbeat.com

OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI

July 19, 2025 | proactiveinvestors.com

OKYO Pharma CEO details positive results from Phase 2 urcosimod trial - ICYMI

July 19, 2025 | proactiveinvestors.com

OKYO Slides Despite Fresh R&D Funding

July 17, 2025 | baystreet.ca

OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain

July 17, 2025 | finance.yahoo.com

OKYO Pharma Secures $1.9 Million to Boost Urcosimod Development

July 17, 2025 | tipranks.com

OKYO Pharma secures $1.9M in non-dilutive funding to advance clinical development of NCP therapy

July 17, 2025 | proactiveinvestors.com

OKYO reports top-line data from neuropathic corneal pain therapy trial

July 17, 2025 | finance.yahoo.com

Okyo sets sights on first approval in neuropathic eye pain after phase 2 win

July 16, 2025 | fiercebiotech.comF

OKYO Pharma shares surge following promising Phase 2 data for eye pain treatment

July 16, 2025 | msn.com

Positive Buy Rating for OKYO Pharma Driven by Promising Phase 2 Trial Results and FDA Fast Track Designation

July 16, 2025 | tipranks.com

OKYO Pharma Reports Promising Phase 2 Results for Urcosimod in Treating Neuropathic Corneal Pain

July 16, 2025 | tipranks.com

OKYO Pharma reports positive Phase 2 results for urcosimod in neuropathic corneal pain

July 16, 2025 | proactiveinvestors.com

OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain

July 16, 2025 | globenewswire.com

OKYO Pharma Limited's (NASDAQ:OKYO) market cap up US$38m last week, benefiting both individual investors who own 58% as well as insiders

June 14, 2025 | uk.finance.yahoo.com

OKYO Pharma to Present at the Bio International Convention

June 11, 2025 | manilatimes.netM

OKYO Pharma poised for breakout as Phase 2 trial nears results: analysts

June 11, 2025 | proactiveinvestors.com

Goldman Small Cap Research Issues New Research Update on OKYO Pharma Limited | OKYO Stock News

June 11, 2025 | gurufocus.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA, CELU, ENTX, and OKYO Company Descriptions

Celularity NASDAQ:CELU

$3.79 +0.18 (+4.99%)

Closing price 03:59 PM Eastern

Extended Trading

$3.80 +0.01 (+0.24%)

As of 04:14 PM Eastern

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

Entera Bio NASDAQ:ENTX

$1.94 -0.01 (-0.51%)

Closing price 04:00 PM Eastern

Extended Trading

$1.94 0.00 (-0.26%)

As of 05:20 PM Eastern

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

Lisata Therapeutics NASDAQ:LSTA

$2.59 +0.12 (+4.86%)

Closing price 03:58 PM Eastern

Extended Trading

$2.60 +0.01 (+0.39%)

As of 04:10 PM Eastern

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

OKYO Pharma NASDAQ:OKYO

$2.37 +0.04 (+1.72%)

Closing price 04:00 PM Eastern

Extended Trading

$2.39 +0.02 (+0.84%)

As of 05:58 PM Eastern

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time